NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. today announced that it will conduct a conference call to review recent developments and progress on Friday, March 12, 2010 at 8:30 a.m. Eastern. Eamonn P. Hobbs, the Company’s President and CEO, and Dave McDonald, the Company’s Chief Financial Officer, will host the conference call and webcast. The dial-in number for the conference call is 877-941-8631 for domestic participants and 480-629-9821 for international participants.
About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of primary and metastatic liver cancers. Delcath’s novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer agents to the liver while controlling the systemic exposure of those agents. In addition to its fully enrolled Phase III metastatic melanoma study, the Company is currently conducting trials to treat other forms of tumor metastases to the liver. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company’s website at www.delcath.com.
CONTACT: Investors, Doug Sherk or Barbara Domingo, +1-415-896-6820, or
media, Steve DiMattia, +1-646-201-5445, all of EVC Group, for Delcath
Systems, Inc.
Web site: http://www.delcath.com/
